AUTL

AUTL

USD

Autolus Therapeutics plc American Depositary Share

$1.410-0.110 (-7.237%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ühendkuningriik

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$1.520

Kõrge

$1.535

Madal

$1.400

Maht

2.28M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

375.3M

Tööstusharu

Biotehnoloogia

Riik

United Kingdom

Kauplemisstatistika

Keskmine maht

3.73M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $1.105Praegune $1.410Kõrge $4.12

Seotud uudised

Analyst Upgrades

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics with a Buy and maintains $10 price target.

Vaata rohkem
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation

Vaata rohkem
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal

Vaata rohkem
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025